An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
- Registry ID
- EUCTR2015-001929-17
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- EISAI LIMITED
- Start date
- 2016-10-20
- Last update
- 2026-08-16
Conditions
- Anaplastic Thyroid Cancer (ATC)
Summary
To evaluate ORR (CR and PR) by investigator review in subjects with ATC treated with lenvatinib.
Locations
View on source registry